Diabetic Ketoacidosis (DKA) Diagnosis: Essential Criteria and Evaluation

Diabetic ketoacidosis (DKA) is a severe and life-threatening complication of diabetes mellitus, primarily associated with type 1 diabetes but also increasingly recognized in type 2 diabetes. It arises from a critical deficiency of insulin coupled with an excess of counter-regulatory hormones, leading to uncontrolled hyperglycemia, metabolic acidosis, and ketonemia. Prompt and accurate diagnosis based on established Ketoacidosis Diagnosis Criteria is crucial for timely intervention and improved patient outcomes. This article provides a comprehensive overview of the diagnostic criteria for DKA, essential evaluation parameters, and clinical considerations for healthcare professionals.

Understanding the Core Diagnostic Criteria for DKA

The diagnosis of diabetic ketoacidosis hinges on a triad of biochemical abnormalities, reflecting the underlying pathophysiology of insulin deficiency and hormonal imbalance. These key ketoacidosis diagnosis criteria are essential for differentiating DKA from other hyperglycemic emergencies and guiding appropriate management strategies.

1. Hyperglycemia: Elevated Blood Glucose Levels

Hyperglycemia, or elevated blood glucose, is a hallmark of DKA. The generally accepted diagnostic threshold for hyperglycemia in DKA is a blood glucose level exceeding 250 mg/dL (13.9 mmol/L). This elevated glucose level is a direct consequence of insulin deficiency, which impairs glucose uptake by peripheral tissues and promotes excessive hepatic glucose production through gluconeogenesis and glycogenolysis.

While hyperglycemia is a defining feature, it’s important to note the phenomenon of euglycemic DKA. In this variant, patients present with the characteristic metabolic acidosis and ketonemia of DKA, but their blood glucose levels may be lower than 250 mg/dL, sometimes even within the normal range. Euglycemic DKA is increasingly recognized, particularly in patients using sodium-glucose cotransporter 2 (SGLT2) inhibitors, during pregnancy, or in cases of starvation. Therefore, while hyperglycemia is a primary criterion, its absence does not rule out DKA, especially in these specific clinical contexts.

2. Metabolic Acidosis: Decreased Arterial pH and Bicarbonate

Metabolic acidosis is a critical component of ketoacidosis diagnosis criteria, reflecting the accumulation of ketone bodies in the bloodstream. This acidosis is characterized by:

Arterial pH less than 7.3: The normal arterial pH range is 7.35-7.45. A pH below 7.3 indicates acidemia, and in the context of DKA, it signifies metabolic acidosis due to the acidic nature of ketones (beta-hydroxybutyrate and acetoacetate).
Serum bicarbonate less than 15 mEq/L: Bicarbonate is the primary buffer in the blood, and its concentration decreases as it neutralizes excess acid. A serum bicarbonate level below 15 mEq/L further confirms metabolic acidosis.

The severity of DKA is often classified based on the degree of acidosis, with severe DKA characterized by a pH less than 7.0 and bicarbonate levels below 10 mEq/L. Arterial blood gas (ABG) analysis is the gold standard for assessing pH and bicarbonate levels, providing the most accurate representation of acid-base status. Venous blood gas (VBG) can be used as an alternative in many situations, although arterial pH is preferred for definitive diagnosis and monitoring in severe cases.

3. Ketonemia or Ketonuria: Presence of Ketones

The presence of ketones in serum (ketonemia) or urine (ketonuria) is the third essential criterion in ketoacidosis diagnosis criteria. Ketones are produced as a byproduct of fatty acid breakdown by the liver when glucose is unavailable as a primary energy source due to insulin deficiency. The major ketone bodies are beta-hydroxybutyrate, acetoacetate, and acetone.

Ketonemia: Refers to elevated ketone levels in the blood. Beta-hydroxybutyrate is the predominant ketone in DKA and is often measured quantitatively for diagnosis and monitoring.
Ketonuria: Indicates the presence of ketones in the urine. Urine ketone testing is a readily available bedside test, often using nitroprusside reagent strips, which primarily detect acetoacetate and acetone, but are less sensitive to beta-hydroxybutyrate.

While both serum and urine ketone tests are valuable, serum ketone measurement, particularly beta-hydroxybutyrate, is considered more accurate and reliable for diagnosing and monitoring DKA resolution. Urine ketones can be positive even after serum ketones have cleared, as urine ketone excretion lags behind serum levels.

Comprehensive Evaluation for DKA Diagnosis

Beyond the core ketoacidosis diagnosis criteria, a comprehensive evaluation is crucial to confirm the diagnosis, assess severity, identify precipitating factors, and guide management. This evaluation includes:

Clinical Assessment: History and Physical Examination

A detailed history and physical examination are essential components of DKA evaluation. Key aspects include:

History of Diabetes: Establish the patient’s known history of diabetes, type of diabetes, current diabetes management regimen (insulin or oral agents), and medication adherence. In new-onset diabetes, DKA may be the presenting manifestation.
Symptoms of Hyperglycemia and Dehydration: Inquire about classic symptoms like polyuria, polydipsia, polyphagia, and weight loss. Symptoms of dehydration, such as decreased urine output, dry mouth, and dizziness, should also be noted.
Gastrointestinal Symptoms: Nausea, vomiting, and abdominal pain are common in DKA and can be significant. Abdominal pain in DKA can be severe and mimic acute abdomen, although it typically resolves with DKA treatment.
Signs of Infection: Infections are frequent precipitants of DKA. Assess for fever, cough, urinary symptoms, or any other signs of infection.
Altered Mental Status: DKA can affect neurological function, ranging from mild drowsiness to confusion, lethargy, and coma in severe cases. Assess the patient’s level of consciousness and neurological status.
Medication History: Review all medications, paying particular attention to potential DKA-precipitating drugs like corticosteroids, thiazide diuretics, sympathomimetic agents, and SGLT2 inhibitors.
Substance Use History: Alcohol and cocaine abuse have been linked to increased risk of DKA.

Physical Examination Findings:

Vital Signs: Tachycardia and tachypnea are common. Hypotension suggests significant dehydration. Fever may indicate infection. Kussmaul breathing (deep, rapid respirations) is a classic sign of metabolic acidosis.
Dehydration Assessment: Evaluate for dry mucous membranes, poor skin turgor, and delayed capillary refill, indicative of volume depletion.
Acetone Breath: A fruity odor to the breath (acetone breath) is a characteristic, though not always present, sign of ketosis.
Abdominal Examination: Assess for abdominal tenderness, which may be present even without underlying abdominal pathology.
Neurological Examination: Evaluate mental status, reflexes, and for any focal neurological deficits, which may suggest cerebral edema (a rare but serious complication).

Laboratory Investigations: Key Parameters for DKA Confirmation

In addition to the core ketoacidosis diagnosis criteria, several laboratory tests are essential for confirming DKA, assessing severity, and guiding management:

Blood Glucose: Measure blood glucose levels to confirm hyperglycemia and monitor response to treatment. Point-of-care glucose testing provides rapid results.
Arterial or Venous Blood Gas (ABG/VBG): Assess pH, bicarbonate, and partial pressure of carbon dioxide (pCO2) to determine the severity of metabolic acidosis and evaluate respiratory compensation. Anion gap, calculated from electrolyte values, is also a key indicator of metabolic acidosis.
Serum Electrolytes: Measure sodium, potassium, chloride, and bicarbonate levels. Electrolyte imbalances are common in DKA, particularly potassium, which can be initially normal or elevated but rapidly decline with insulin therapy. Corrected sodium should be calculated to account for hyperglycemia-induced hyponatremia.
Serum Ketones (Beta-hydroxybutyrate): Quantitatively measure serum beta-hydroxybutyrate levels for accurate diagnosis and monitoring of ketosis resolution.
Urine Ketones: Qualitative urine ketone testing can be done as a rapid bedside test, but serum ketones are preferred for accuracy.
Complete Blood Count (CBC): Leukocytosis is common in DKA, even without infection, due to stress response. However, a significantly elevated white blood cell count may suggest infection.
Renal Function Tests (BUN, Creatinine): Assess renal function, which may be impaired due to dehydration and hyperosmolarity.
Serum Osmolality: Calculate serum osmolality, which is often elevated in DKA due to hyperglycemia and hypernatremia.
Anion Gap: Calculate the anion gap ([Na+] – [Cl-] – [HCO3-]) to confirm the presence of high anion gap metabolic acidosis, a hallmark of DKA. An anion gap greater than 12 mEq/L is typically considered elevated.

Optional and Context-Dependent Investigations:

Glycated Hemoglobin (HbA1c): Provides information about long-term glycemic control and can help differentiate between chronic poor control and acute DKA in known diabetics, or suggest pre-existing undiagnosed diabetes in new-onset DKA.
Serum Lipase: Elevated serum lipase and amylase can be seen in DKA, even without pancreatitis. However, if abdominal pain is severe or pancreatitis is suspected, serum lipase should be measured, and imaging (CT scan) may be considered to rule out pancreatitis.
Electrocardiogram (ECG): Assess for cardiac arrhythmias or ECG changes related to electrolyte imbalances, particularly hyperkalemia or hypokalemia.
Chest X-ray: If pneumonia is suspected as a precipitating factor, a chest X-ray should be performed.
Blood Cultures, Urine Cultures, Sputum Cultures: If infection is suspected, obtain appropriate cultures to identify the causative organism.

Differentiating DKA from Other Conditions: Differential Diagnosis

While the ketoacidosis diagnosis criteria are specific, it’s essential to consider other conditions that may mimic DKA, particularly in the initial presentation. Differential diagnoses include:

Hyperosmolar Hyperglycemic State (HHS): Another hyperglycemic emergency, but characterized by profound hyperglycemia and hyperosmolality without significant ketosis or acidosis. Differentiating features include the degree of ketosis and acidosis, and serum osmolality, which is much higher in HHS.
Alcoholic Ketoacidosis (AKA): Occurs in chronic alcohol users and is characterized by metabolic acidosis and ketosis, but often with hypoglycemia or mild hyperglycemia. History of alcohol abuse is key.
Starvation Ketosis: Mild ketosis and acidosis due to prolonged fasting or severe calorie restriction. Blood glucose is typically low or normal.
Lactic Acidosis: Elevated lactic acid levels causing metabolic acidosis. Can be due to sepsis, shock, tissue hypoperfusion, or certain medications. Lactic acidosis typically lacks significant ketosis and hyperglycemia.
Toxic Ingestions: Ingestion of toxins like ethylene glycol, methanol, or salicylate can cause high anion gap metabolic acidosis. History and toxicology screening are important.
Renal Failure (Uremic Acidosis): Severe renal failure can cause metabolic acidosis, but typically not associated with significant ketosis or hyperglycemia.
Pancreatitis: Can present with abdominal pain and elevated lipase, potentially mimicking DKA-related abdominal pain. However, pancreatitis does not typically cause hyperglycemia or ketosis unless it leads to diabetes.

Conclusion: Timely Diagnosis Based on Ketoacidosis Diagnosis Criteria

Accurate and timely diagnosis of diabetic ketoacidosis is paramount for effective management and prevention of serious complications. Adherence to the established ketoacidosis diagnosis criteria – hyperglycemia, metabolic acidosis, and ketonemia – combined with a comprehensive clinical and laboratory evaluation, allows for prompt identification of DKA. Healthcare professionals must be vigilant in recognizing the signs and symptoms of DKA, especially in patients with diabetes, and initiate appropriate diagnostic and therapeutic measures without delay. Understanding the nuances of DKA diagnosis, including euglycemic DKA and differential diagnoses, is essential for optimizing patient care and improving outcomes in this critical condition.

References

[List of references from the original article, ensuring they are correctly formatted and numbered]

1.Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43.
2.Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52.
3.Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017;2017
4.Gosmanov AR, Kitabchi AE. Diabetic Ketoacidosis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Apr 28, 2018.
5.Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017 Aug 01;7(7):e016587.
6.Große J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression. Horm Metab Res. 2018 Mar;50(3):209-222.
7.Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med. 1991 Nov-Dec;6(6):495-502.
8.Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997 Mar 24;157(6):669-75.
9.Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality – United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):362-365.
10.Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care. 2006 Sep;29(9):2018-22.
11.Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am. 2004 Jul;88(4):1063-84, xii.
12.Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7224-7.
13.Barnes AJ, Bloom SR, Goerge K, Alberti GM, Smythe P, Alford FP, Chisholm DJ. Ketoacidosis in pancreatectomized man. N Engl J Med. 1977 Jun 02;296(22):1250-3.
14.Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet. 1973 Sep 22;2(7830):635-9.
15.Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care. 2002 Mar;17(1):63-7.
16.Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am. 1995 Jan;79(1):39-52.
17.Umpierrez GE, Khajavi M, Kitabchi AE. Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Am J Med Sci. 1996 May;311(5):225-33.
18.Paulson WD, Gadallah MF. Diagnosis of mixed acid-base disorders in diabetic ketoacidosis. Am J Med Sci. 1993 Nov;306(5):295-300.
19.Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001 Jan;24(1):131-53.
20.Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med. 1980 Aug;93(2):280-1.
21.Warshaw AL, Feller ER, Lee KH. On the cause of raised serum-amylase in diabetic ketoacidosis. Lancet. 1977 Apr 30;1(8018):929-31.
22.Vantyghem MC, Haye S, Balduyck M, Hober C, Degand PM, Lefebvre J. Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes. Acta Diabetol. 1999 Jun;36(1-2):39-44.
23.Weidman SW, Ragland JB, Fisher JN, Kitabchi AE, Sabesin SM. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J Lipid Res. 1982 Jan;23(1):171-82.
24.Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000567.
25.Mahler SA, Conrad SA, Wang H, Arnold TC. Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. Am J Emerg Med. 2011 Jul;29(6):670-4.
26.Chua HR, Venkatesh B, Stachowski E, Schneider AG, Perkins K, Ladanyi S, Kruger P, Bellomo R. Plasma-Lyte 148 vs 0.9% saline for fluid resuscitation in diabetic ketoacidosis. J Crit Care. 2012 Apr;27(2):138-45.
27.Van Zyl DG, Rheeder P, Delport E. Fluid management in diabetic-acidosis–Ringer’s lactate versus normal saline: a randomized controlled trial. QJM. 2012 Apr;105(4):337-43.
28.Adrogué HJ, Barrero J, Eknoyan G. Salutary effects of modest fluid replacement in the treatment of adults with diabetic ketoacidosis. Use in patients without extreme volume deficit. JAMA. 1989 Oct 20;262(15):2108-13.
29.Edge JA, Jakes RW, Roy Y, Hawkins M, Winter D, Ford-Adams ME, Murphy NP, Bergomi A, Widmer B, Dunger DB. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia. 2006 Sep;49(9):2002-9.
30.Gosmanov AR, Gosmanova EO, Kitabchi AE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): May 9, 2021.
31.Kitabchi AE, Murphy MB, Spencer J, Matteri R, Karas J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care. 2008 Nov;31(11):2081-5.
32.Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004 Sep 01;117(5):291-6.
33.Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine. 2018 Aug;61(2):267-274.
34.Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016 Apr;65(4):507-21.
35.Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014 Nov;37(11):3124-31.
36.Herpes virus fingerprinting. Lancet. 1979 Feb 03;1(8110):251-2.
37.Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017 May;101(3):587-606.
38.Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR, Hughes DW. Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. Ann Pharmacother. 2013 Jul-Aug;47(7-8):970-5.
39.Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N., Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001 Jan 25;344(4):264-9.
40.Osuka A, Matsuoka T, Idoguchi K. Is this the worst outcome of metabolic syndrome? Hypophosphatemia and resulting cardiac arrest during the treatment of diabetic ketoacidosis with hypertriglyceridemia. Intern Med. 2009;48(16):1391-5.
41.Regmi A, Konstantinov NK, Agaba EI, Rohrscheib M, Dorin RI, Tzamaloukas AH. Respiratory Failure in the Course of Treatment of Diabetic Ketoacidosis. Clin Diabetes. 2014 Jan;32(1):28-31.
42.Abbas Q, Arbab S, Haque AU, Humayun KN. Spectrum of complications of severe DKA in children in pediatric Intensive Care Unit. Pak J Med Sci. 2018 Jan-Feb;34(1):106-109.
43.Kutlu AO, Kara C, Cetinkaya S. Rhabdomyolysis without detectable myoglobulinuria due to severe hypophosphatemia in diabetic ketoacidosis. Pediatr Emerg Care. 2011 Jun;27(6):537-8.
44.Konstantinov NK, Rohrscheib M, Agaba EI, Dorin RI, Murata GH, Tzamaloukas AH. Respiratory failure in diabetic ketoacidosis. World J Diabetes. 2015 Jul 25;6(8):1009-23.